Enhancing race-based prescribing precision with pharmacogenomics

A. Nguyen, Zeruesenay Desta, D. A. Flockhart

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the world of medicine and therapeutics, race and ethnicity might reasonably be considered as biomarkers or predictors of drug effect. Recognizing that all biomarkers are imperfect, self-reported race can be viewed as a complex combination of genetic and nongenetic biomarkers that is used by prescribing physicians as a predictor of drug effect. The use of pharmacogenetic markers, such as haplotypes, patterns of candidate genes, and specific genotypes, may be used to enhance the precision of race-based prescribing and, when possible, should be combined with nongenetic predictors of responses to optimize the individualization of therapy.

Original languageEnglish
Pages (from-to)323-325
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume81
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Pharmacogenetics
Biomarkers
Pharmaceutical Preparations
Haplotypes
Genotype
Medicine
Physicians
Therapeutics
Genes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Enhancing race-based prescribing precision with pharmacogenomics. / Nguyen, A.; Desta, Zeruesenay; Flockhart, D. A.

In: Clinical Pharmacology and Therapeutics, Vol. 81, No. 3, 03.2007, p. 323-325.

Research output: Contribution to journalArticle

@article{bb31f69f8d2b4c97963c662b943f62a2,
title = "Enhancing race-based prescribing precision with pharmacogenomics",
abstract = "In the world of medicine and therapeutics, race and ethnicity might reasonably be considered as biomarkers or predictors of drug effect. Recognizing that all biomarkers are imperfect, self-reported race can be viewed as a complex combination of genetic and nongenetic biomarkers that is used by prescribing physicians as a predictor of drug effect. The use of pharmacogenetic markers, such as haplotypes, patterns of candidate genes, and specific genotypes, may be used to enhance the precision of race-based prescribing and, when possible, should be combined with nongenetic predictors of responses to optimize the individualization of therapy.",
author = "A. Nguyen and Zeruesenay Desta and Flockhart, {D. A.}",
year = "2007",
month = "3",
doi = "10.1038/sj.clpt.6100080",
language = "English",
volume = "81",
pages = "323--325",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Enhancing race-based prescribing precision with pharmacogenomics

AU - Nguyen, A.

AU - Desta, Zeruesenay

AU - Flockhart, D. A.

PY - 2007/3

Y1 - 2007/3

N2 - In the world of medicine and therapeutics, race and ethnicity might reasonably be considered as biomarkers or predictors of drug effect. Recognizing that all biomarkers are imperfect, self-reported race can be viewed as a complex combination of genetic and nongenetic biomarkers that is used by prescribing physicians as a predictor of drug effect. The use of pharmacogenetic markers, such as haplotypes, patterns of candidate genes, and specific genotypes, may be used to enhance the precision of race-based prescribing and, when possible, should be combined with nongenetic predictors of responses to optimize the individualization of therapy.

AB - In the world of medicine and therapeutics, race and ethnicity might reasonably be considered as biomarkers or predictors of drug effect. Recognizing that all biomarkers are imperfect, self-reported race can be viewed as a complex combination of genetic and nongenetic biomarkers that is used by prescribing physicians as a predictor of drug effect. The use of pharmacogenetic markers, such as haplotypes, patterns of candidate genes, and specific genotypes, may be used to enhance the precision of race-based prescribing and, when possible, should be combined with nongenetic predictors of responses to optimize the individualization of therapy.

UR - http://www.scopus.com/inward/record.url?scp=33847628842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847628842&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100080

DO - 10.1038/sj.clpt.6100080

M3 - Article

VL - 81

SP - 323

EP - 325

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -